Investorideas.com newswire, news and commentary for leading sectors

Wednesday, September 05, 2012

Biotech Stock Trading Alert: Sunshine Biopharma (OTCBB: SBFM) Shares Gain over 12% on news of Delivery of Lead Anti-Cancer Compound Adva-27a

New York, New York - September 5, 2012 (Investorideas.com Newswire, www.biotechindustrystocks.com) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks issues a trading alert for Sunshine Biopharma Inc. (OTCBB: SBFM) as of the close of trading September 4 th , following news that it has taken delivery of an initial batch of Adva-27a.

Now that the Company has taken delivery from the Contract Manufacturing Organization (CMO) it will proceed to conduct a series of requisite biological tests to ensure that the newly manufactured batch is identical to the original, not only in terms of chemical structure but also in terms of biological activity. Among the tests we will be performing are Topoisomerase II inhibition assays and cytotoxicity evaluations. The Topoisomerase II inhibition tests are already underway and the cytotoxicity evaluations will be initiated later this week. Adva-27a is Sunshine Biopharma's lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
Sunshine Biopharma's lead compound, Adva-27a, is an effective and highly specific Topoisomerase II (Top2) Inhibitor and has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
Mr. Camille Sebaaly, CFO, previously commented as to the significance of this stage of drug development, "The Scale-up Manufacturing Protocol, the second part of the delivery from Beta Pharma Canada, will be confirmed by Sunshine Biopharma then transferred to the large-scale (over 1 kilogram range) manufacturer for large-scale process development and manufacturing under GMP conditions. The material produced under GMP condition will be used by Sunshine Biopharma to conduct IND-Enabling Studies and Phase I Clinical Trials in humans."
Investorideas.com Newswire Read Investorideas.com First Q&A Interview with Mr. Camille Sebaaly, CFO
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp
About Beta Pharma Canada
Beta Pharma Canada Inc. is an affiliate of Beta Pharma Inc. with offices and facilities in Connecticut (USA) and Shanghai ( China). Beta Pharma Canada Inc., headquartered in Montreal ( Canada), is a Canadian small-molecule drug discovery and manufacturing company specializing in design, synthesis and process development of novel pharmaceutical compounds.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
Post a Comment

InvestorIdeas.com Newswire